Score of Milojkovic et al Predicting Response of a Patient with Chronic Myelogenous Leukemia (CML) to a Second Generation Tyrosine Kinase Inhibitor

Description

Milojkovic et al developed a score for predicting the response of a patient with chronic myelogenous leukemia (CML) to second generation tyrosine kinase inhibitors. The authors are from Hammersmith Hospitals, Imperial College London, Beatson West of Scotland Cancer Center, University of Glasgow, and the Western General Hospital in Edinburgh.

Patient selection: chronic myelogenous leukemia (CML)

Parameters:

(1) best cytogenetic response to imatinib

(2) Sokal risk group (28.12.04)

(3) neutropenia during imatinib therapy

Parameter	Finding	Points
best cytogenetic response	complete remission (0% Ph-positive metaphases)	0
	1 to 94% Ph-positive metaphases	1
	95-100% Ph-positive metaphases	3
Sokal risk group	low	0
	intermediate	0.5
	high	0.5
neutropenia during imatinib	none	0
	recurrent episodes of Grade III or IV neutropenia requiring dose reduction	1

total score =

= SUM(points for all 3 paramters)

Interpretation:

• minimum score: 0

• maximum score: 4.5

• The higher the score the greater the risk of a incomplete response to therapy with a second generation tyrosine kinase inhibitor.

Total Score	Risk Group	Complete Cytogenetic Response at 2 Years
0, 0.5, 1	good	100%
1.5, 2.0, 2.5	intermediate	52-63%
3, 3.5. 4, 4.5	poor	14-17%

To read more or access our algorithms and calculators, please log in or register.

Score of Milojkovic et al Predicting Response of a Patient with Chronic Myelogenous Leukemia (CML) to a Second Generation Tyrosine Kinase Inhibitor

Description

Specialty